1
|
Fattal E, Tsapis N, Phan G. Novel drug delivery systems for actinides (uranium and plutonium) decontamination agents. Adv Drug Deliv Rev 2015; 90:40-54. [PMID: 26144994 DOI: 10.1016/j.addr.2015.06.009] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2015] [Revised: 06/18/2015] [Accepted: 06/24/2015] [Indexed: 12/17/2022]
Abstract
The possibility of accidents in the nuclear industry or of nuclear terrorist attacks makes the development of new decontamination strategies crucial. Among radionuclides, actinides such as uranium and plutonium and their different isotopes are considered as the most dangerous contaminants, plutonium displaying mostly a radiological toxicity whereas uranium exhibits mainly a chemical toxicity. Contamination occurs through ingestion, skin or lung exposure with subsequent absorption and distribution of the radionuclides to different tissues where they induce damaging effects. Different chelating agents have been synthesized but their efficacy is limited by their low tissue specificity and high toxicity. For these reasons, several groups have developed smart delivery systems to increase the local concentration of the chelating agent or to improve its biodistribution. The aim of this review is to highlight these strategies.
Collapse
|
2
|
Huckle JE, Sadgrove MP, Pacyniak E, Leed MGD, Weber WM, Doyle-Eisele M, Guilmette RA, Agha BJ, Susick RL, Mumper RJ, Jay M. Orally administered DTPA di-ethyl ester for decorporation of (241)Am in dogs: Assessment of safety and efficacy in an inhalation-contamination model. Int J Radiat Biol 2015; 91:568-75. [PMID: 25912343 DOI: 10.3109/09553002.2015.1043753] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
PURPOSE Currently two injectable products of diethylenetriaminepentaacetic acid (DTPA) are U.S. Food and Drug Administration (FDA)-approved for decorporation of (241)Am; however, an oral product is considered more amenable in a mass casualty situation. The di-ethyl ester of DTPA, named C2E2, is being developed as an oral drug for treatment of internal radionuclide contamination. MATERIALS AND METHODS Single-dose decorporation efficacy of C2E2 administered 24-h post contamination was determined in beagle dogs using a (241)Am nitrate inhalation contamination model. Single and multiple dose toxicity studies in beagle dogs were performed as part of an initial safety assessment program. In addition, the genotoxic potential of C2E2 was evaluated by the in vitro bacterial reverse mutation Ames test, mammalian cell chromosome aberration cytogenetic assay and an in vivo micronucleus test. RESULTS Oral administration of C2E2 significantly increased (241)Am elimination over untreated controls and significantly reduced the retention of (241)Am in tissues, especially liver, kidney, lung and bone. Daily dosing of 200 mg/kg/day for 10 days was well tolerated in dogs. C2E2 was found to be neither mutagenic or clastogenic. CONCLUSIONS The di-ethyl ester of DTPA (C2E2) was shown to effectively enhance the elimination of (241)Am after oral administration in a dog inhalation-contamination model and was well tolerated in toxicity studies.
Collapse
Affiliation(s)
- James E Huckle
- University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Molecular Pharmaceutics , Chapel Hill , NC
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Wilson JP, Cobb RR, Dungan NW, Matthews LL, Eppler B, Aiello KV, Curtis S, Boger T, Guilmette RA, Weber W, Doyle-Eisele M, Talton JD. Decorporation of systemically distributed americium by a novel orally administered diethylenetriaminepentaacetic acid (DTPA) formulation in beagle dogs. HEALTH PHYSICS 2015; 108:308-318. [PMID: 25627942 DOI: 10.1097/hp.0000000000000199] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Novel decorporation agents are being developed to protect against radiological accidents and terrorists attacks. Radioactive americium is a significant component of nuclear fallout. Removal of large radioactive materials, such as 241Am, from exposed persons is a subject of significant interest due to the hazards they pose. The objective of this study was to evaluate the dose-related efficacy of daily doses of NanoDTPA™ Capsules for decorporating Am administered intravenously as a soluble citrate complex to male and female beagle dogs. In addition, the efficacy of the NanoDTPA™ Capsules for decorporating 241Am was directly compared to intravenously administered saline and DTPA. Animals received a single IV administration of 241Am(III)-citrate on Day 0. One day after radionuclide administration, one of four different doses of NanoDTPA™ Capsules [1, 2, or 6 capsules d(-1) (30 mg, 60 mg, or 180 mg DTPA) or 2 capsules BID], IV Zn-DTPA (5 mg kg(-1) pentetate zinc trisodium) as a positive control, or IV saline as a placebo were administered. NanoDTPA™ Capsules, IV Zn-DTPA, or IV saline was administered on study days 1-14. Animals were euthanized on day 21. A full necropsy was conducted, and liver, spleen, kidneys, lungs and trachea, tracheobronchial lymph nodes (TBLN), muscle samples (right and left quadriceps), gastrointestinal (GI) tract (stomach plus esophagus, upper and lower intestine), gonads, two femurs, lumbar vertebrae (L1-L4), and all other soft tissue remains were collected. Urinary and fecal excretion profiles were increased approximately 10-fold compared to those for untreated animals. Tissue contents were decreased compared to untreated controls. In particular, liver content was decreased by approximately eightfold compared to untreated animals. The results from this study further demonstrate that oral NanoDTPA™ Capsules are equally efficient compared to IV Zn-DTPA in decorporation of actinides.
Collapse
Affiliation(s)
- James P Wilson
- *Nanotherapeutics, Inc., Alachua, FL 32615; †Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Reddy JD, Cobb RR, Dungan NW, Matthews LL, Aiello KV, Ritter G, Eppler B, Kirk JF, Abernethy JA, Tomisaka DM, Talton JD. Preclinical Toxicology, Pharmacology, and Efficacy of a Novel Orally Administered Diethylenetriaminepentaacetic acid (DTPA) Formulation. Drug Dev Res 2012. [DOI: 10.1002/ddr.21018] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
5
|
Sadgrove MP, Leed MGD, Shapariya S, Madhura DB, Jay M. Evaluation of a DTPA Prodrug, C2E5 as an Orally Bioavailable Radionuclide Decorporation Agent. Drug Dev Res 2012. [DOI: 10.1002/ddr.21019] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Matthew P. Sadgrove
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill; NC; 27599-7362; USA
| | - Marina G. D. Leed
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill; NC; 27599-7362; USA
| | - Shraddha Shapariya
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill; NC; 27599-7362; USA
| | - Dora Babu Madhura
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill; NC; 27599-7362; USA
| | - Michael Jay
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy; University of North Carolina at Chapel Hill; Chapel Hill; NC; 27599-7362; USA
| |
Collapse
|
6
|
Sueda K, Sadgrove MP, Fitzsimmons JM, Jay M. Physicochemical characterization of a prodrug of a radionuclide decorporation agent for oral delivery. J Pharm Sci 2012; 101:2844-53. [PMID: 22644947 DOI: 10.1002/jps.23218] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2012] [Revised: 05/08/2012] [Accepted: 05/09/2012] [Indexed: 12/12/2022]
Abstract
Intravenously administered calcium and zinc complexes of diethylenetriaminepentaacetic acid (DTPA) are the agents of choice to treat individuals who have been contaminated with radioactive actinides. However, their use in a mass casualty scenario is hampered by the need for trained personnel to receive treatment. Because DTPA is a highly ionized molecule with permeability-limited bioavailability, the penta-ethyl ester prodrug of DTPA is under evaluation as an orally bioavailable radionuclide decorporation agent. In this work, the physicochemical properties of DTPA penta-ethyl ester were characterized to assess its potential for oral delivery. DTPA penta-ethyl ester was determined to be a low-viscosity liquid with Newtonian flow characteristics. Consistent with the measured pK(a) values, which range from 2.93 to 10.87, this prodrug exhibits pH-dependent solubility and lipophilicity properties that are representative of a weak base and favorable for oral absorption. It is miscible in solvents that are nonpolar to moderately polar and is sufficiently stable to avoid premature hydrolysis during gastrointestinal transit. Therapeutic effects were demonstrated in an initial efficacy study wherein oral treatments of the prodrug were given to rats contaminated with ²⁴¹Am, providing preliminary indications of successful oral delivery. The properties of the prodrug indicate that it is conducive to oral delivery and may offer therapeutic benefits over the standard DTPA therapy following radionuclide contamination.
Collapse
Affiliation(s)
- Katsuhiko Sueda
- Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina 27599, USA
| | | | | | | |
Collapse
|
7
|
Miller SC, Wang X, Bowman BM. Pharmacological properties of orally available, amphipathic polyaminocarboxylic acid chelators for actinide decorporation. HEALTH PHYSICS 2010; 99:408-412. [PMID: 20699705 PMCID: PMC2921225 DOI: 10.1097/hp.0b013e3181bfb99b] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Commonly used water-soluble polyaminocarboxylic acid (PACA) chelators, such as EDTA and DTPA, require intravenous or subcutaneous administration due to their poor bioavailability. The bioavailability of PACAs can be improved by the addition of differing lengths of alkyl side chains that alter amphipathic properties. Orally administered amphipathic triethylenetetramine pentaacetic acid (TT) compounds are efficacious for decorporation of plutonium and americium. The synthesis, efficacy, binding affinities, and some initial pharmacokinetics properties of amphipathic TT chelators are reviewed. C-labeled C12TT and C22TT chelators are reasonably well absorbed from the intestine and have a substantial biliary/fecal excretion pathway, unlike DTPA, which is mostly excreted in the urine. Whole body retention times are increased as a function of increasing lipophilicity. Neutron-induced autoradiography studies demonstrate that the oral administration of the chelators can substantially inhibit the redistribution of Pu in skeletal tissues. In summary, amphipathic TT-based chelators have favorable bioavailability, have a significant biliary excretion pathway, have demonstrated efficacy for americium and plutonium, and are thus good candidates for further development. Furthermore, some of the pharmacological properties can be manipulated by changing the lengths of the alkyl side chains and this may have some advantage for decorporation of certain metals and radionuclides.
Collapse
Affiliation(s)
- Scott C Miller
- Division of Radiobiology, University of Utah, Salt Lake City, UT 84108, USA.
| | | | | |
Collapse
|
8
|
Liu G, Men P, Kenner GH, Miller SC. Therapeutic Effects of an Oral Chelator Targeting Skeletal Tissue Damage in Experimental Postmenopausal Osteoporosis in Rats. Hemoglobin 2009; 32:181-90. [DOI: 10.1080/03630260701726707] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
9
|
Abstract
All of the actinides are radioactive. Taken into the body, they damage and induce cancer in bone and liver, and in the lungs if inhaled, and U(VI) is a chemical kidney poison. Containment of radionuclides is fundamental to radiation protection, but if it is breached accidentally or deliberately, decontamination of exposed persons is needed to reduce the consequences of radionuclide intake. The only known way to reduce the health risks of internally deposited actinides is to accelerate their excretion with chelating agents. Ethylendiaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA) were introduced in the 1950's. DTPA is now clinically accepted, but its oral activity is low, it must be injected as a Ca(II) or Zn(II) chelate to avoid toxicity, and it is structurally unsuitable for chelating U(VI) or Np(V). Actinide penetration into the mammalian iron transport and storage systems suggested that actinide ions would form stable complexes with the Fe(III)-binding units found in potent selective natural iron chelators (siderophores). Testing of that biomimetic approach began in the late 1970's with the design, production, and assessment for in vivo Pu(IV) chelation of synthetic multidentate ligands based on the backbone structures and Fe(III)-binding groups of siderophores. New efficacious actinide chelators have emerged from that program, in particular, octadentate 3,4,3-LI(1,2-HOPO) and tetradentate 5-LIO(Me-3,2-HOPO) have potential for clinical acceptance. Both are much more effective than CaNa3-DTPA for decorporation of Pu(IV), Am(III), U(VI), and Np(IV,V), they are orally active, and toxicity is acceptably low at effective dosage.
Collapse
Affiliation(s)
- Patricia W Durbin
- Division of Chemical Sciences, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
| |
Collapse
|
10
|
Sonoda M, Yoshida I, Murase I. SYNTHESIS AND DETERMINATION OF METAL CHELATE STABILITIES OF n-ALKYLTRIETHYLENETETRA AMINEPENTAACETIC ACID. J COORD CHEM 2006. [DOI: 10.1080/00958970108027151] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
- Miwako Sonoda
- a Department of Applied Chemistry , Kumamoto Institute of Technology , 4-Ikeda, Kumamoto, 860-0082, Japan
| | - Isao Yoshida
- a Department of Applied Chemistry , Kumamoto Institute of Technology , 4-Ikeda, Kumamoto, 860-0082, Japan
| | - Ichiro Murase
- b Dojindo Laboratories Co. , Mashiki-machi, Kumamoto, 861-2202, Japan
| |
Collapse
|
11
|
Liu G, Men P, Kenner GH, Miller SC. Age-associated Iron Accumulation in Bone: Implications for Postmenopausal Osteoporosis and a New Target for Prevention and Treatment by Chelation. Biometals 2006; 19:245-51. [PMID: 16691320 DOI: 10.1007/s10534-005-6666-2] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2005] [Accepted: 04/29/2005] [Indexed: 10/24/2022]
Abstract
Iron accumulation in tissues is believed to be a characteristic of aged humans and a risk factor for some chronic diseases. However, it is not known whether age-associated iron accumulation is part of the pathogenesis of postmenopausal osteoporosis that affects approximately one out three women worldwide. Here, we confirmed that this accumulation of iron was associated with osteopenia in ovariectomized (OVX) rats (a model of peri- and postmenopausal osteoporosis due to estrogen deficiency). To further investigate whether the increased iron level plays a causal role in the onset of bone loss, we treated OVX rats with an orally active and bone targeted chelator that prevented iron accumulation in their skeletal tissues. The results showed that this treatment mitigated the loss of bone mass and the deterioration of bone micro-architecture. We also found that one possible mechanism of the protective action of iron chelation was to significantly reduce bone resorption. Thus, these findings provide a novel target and a potentially useful therapeutic strategy for the prevention and treatment of postmenopausal osteoporosis and perhaps other age-related diseases.
Collapse
Affiliation(s)
- Gang Liu
- Radiobiology Division, Department of Radiology, School of Medicine, University of Utah, 729 Arapeen Dr. Suite 2334, Salt Lake City, UT 84108, USA.
| | | | | | | |
Collapse
|
12
|
Miller SC, Liu G, Bruenger FW, Lloyd RD. Efficacy of orally administered amphipathic polyaminocarboxylic acid chelators for the removal of plutonium and americium: comparison with injected Zn-DTPA in the rat. RADIATION PROTECTION DOSIMETRY 2006; 118:412-20. [PMID: 16332916 DOI: 10.1093/rpd/nci367] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Chelators are used to promote excretion of actinides and some other metals, but few are orally effective. The relative efficacies of orally administered triethylenetetraminepentaacetic acids (TT) with varying lipophilic properties on the removal of 241Am and 239Pu and comparison with parenteral Zn-DTPA was determined. The actinides were administered to adult rats 2 weeks prior to initiation of 30 d of chelation treatment. The TT compounds were given orally while Zn-DTPA was given twice weekly by injection. Total body content of 241Am was measured before and during the treatment period and organ contents of 241Am and 239Pu were measured at the end of the study. Significant reductions in 241Am occurred within the first week, with Zn-DTPA being the most effective. By 3 weeks, the most lipophilic chelator, C22TT was as effective as Zn-DTPA. After 30 d, reductions in organ content of 239Pu and 241Am directly correlated with increasing lipophilicity of the TT chelators. Oral C22TT was as effective as injected Zn-DTPA in liver and bone, the major organs of actinide deposition. The removal of 239Pu from the liver and reduction of redeposition of 239Pu in newly formed bone by C22TT was confirmed by neutron-induced autoradiographs. The amphipathic TT chelators may be useful as orally administered alternatives to current parenteral DTPA for the removal of actinide elements from the body, particularly for longer-term therapeutic applications.
Collapse
Affiliation(s)
- Scott C Miller
- Division of Radiobiology, Department of Radiology, University of Utah, 729 Arapeen Drive, Salt Lake City, Utah 84108, USA.
| | | | | | | |
Collapse
|
13
|
Gorden AEV, Xu J, Raymond KN, Durbin P. Rational Design of Sequestering Agents for Plutonium and Other Actinides. Chem Rev 2003; 103:4207-82. [PMID: 14611263 DOI: 10.1021/cr990114x] [Citation(s) in RCA: 432] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Anne E V Gorden
- Department of Chemistry, University of California, Berkeley, California 94720, USA
| | | | | | | |
Collapse
|
14
|
Liu G, Miller SC, Bruenger FW. Synthesis of Lipophilic 3-Hydroxy-2-methyl-4-pyridinone Derivatives. SYNTHETIC COMMUN 1995. [DOI: 10.1080/00397919508015476] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|